{
    "clinical_study": {
        "@rank": "53519", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo once weekly"
            }, 
            {
                "arm_group_label": "3 mg LD-Aminopterin", 
                "arm_group_type": "Experimental", 
                "description": "3 mg LD-aminopterin once weekly"
            }, 
            {
                "arm_group_label": "1 mg LD-aminopterin", 
                "arm_group_type": "Experimental", 
                "description": "1 mg LD-aminopterin once weekly"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether aminopterin is effective in the treatment\n      of rheumatoid arthritis (RA)."
        }, 
        "brief_title": "Aminopterin Dose Finding Treatment for Methotrexate-Na\u00efve Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, placebo-controlled, dose ranging study that will\n      evaluate the safety, efficacy, and pharmacokinetic properties (the absorption, distribution\n      and excretion) of aminopterin following oral administration by subjects with active\n      rheumatoid arthritis (\u2265 6 tender and \u2265 6 swollen joints) who have not been treated with\n      methotrexate (MTX).  Subjects are randomized to one of three treatments: placebo, 1 mg of\n      LD-aminopterin, or 3 mg of LD-aminopterin in a 1:1:1 ratio.  The study hypothesis is that\n      the 3 mg LD-aminopterin per week is effective at treating rheumatoid arthritis compared to\n      placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. > 18 years of age.\n\n          2. A diagnosis of RA established by the ACR/EULAR 2010 criteria applied to patients who:\n             1) have >1 joint with definite clinical synovitis (swelling); 2) with the synovitis\n             not better explained by another disease.\n\n        Add scores of categories A-D; a score >6/10 is required for study entry.\n\n        A. Joint involvement:\n\n        1 large joint=0; 2-10 large joints=1; 1-3 small joints (with or without involvement of\n        large joints=2; 4-10 small joints (with or without involvement of large joints)=3; >10\n        joints (at least 1 small joint)=5.\n\n        B. Serology (at least 1 test result is needed for classification):\n\n        Negative RF and negative ACPA=0; Low-positive RF or low-positive ACPA=2; High-positive RF\n        or high-positive ACPA=3.\n\n        C. Acute-phase reactants (at least 1 test result is needed for classification):\n\n        Normal CRP and normal ESR=0; Abnormal CRP or abnormal ESR=1.\n\n        D. Duration of symptoms:\n\n        less than 6 weeks=0; 6 weeks or greater=1.\n\n        3. Class I, II or III functional according to the ACR 1992 revised criteria for the\n        classification of global functional status in RA.\n\n        4. RA is active, defined as \u2265 6 swollen joints and \u2265 6 tender joints.\n\n        5. Ability to understand and sign written informed consent.\n\n        6. For sexually active men and for women of childbearing potential, an adequate form of\n        contraception.\n\n        7. For pre-menopausal women, a negative pregnancy test, obtained within 1 week prior to\n        first study drug dose.\n\n        8. Negative serology for hepatitis B and hepatitis C.\n\n        9. The following screening laboratory blood tests must have the following values, or not\n        clinically significant as determined by the PI and Medical Monitor: WBC WNL; absolute\n        neutrophil count > lower limit of normal; platelet count WNL; hemoglobin >10.0 g/dL; AST\n        WNL.\n\n        10. Adequate renal function: GFR estimated by Cockcroft-Gault formula >60 ml/min\n\n        Exclusion Criteria:\n\n          1. Known history of hepatitis, HIV infection, interstitial lung disease.\n\n          2. Alcohol consumption on a regular basis and unwilling, or unable, to discontinue this\n             consumption during the study period.\n\n          3. Prior methotrexate or aminopterin therapy.\n\n          4. Prior biologic drug therapy (e.g., etanercept, adalimumab, infliximab).\n\n          5. Within 2 weeks prior to Study Day 0,  or on Study Day 0, or at any time during the\n             study, use of any of the following medications that may result in drug/drug\n             interactions with AMT: trimethoprim with or without sulfamethoxazole; sulfonamides;\n             sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid;\n             aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin).\n\n          6. At Study Day 0 use of DMARDs and biologics (except antimalarials) including oral or\n             injectable gold, azathioprine, penicillamine, sulfasalazine or cyclosporine.\n             Subjects previously treated with any of these medications are eligible provided a 28\n             day wash-out is completed prior to Study Day 0.  Antimalarial can be continued at the\n             same dose if they have been administered at the same dose for 8 weeks before Study\n             Day 0, and they will be administered at the same dose throughout the study.  NSAIDs\n             or corticosteroid (\u2264 10 mg prednisone or equivalent/day) may be continued at the same\n             dose if they have been used at a stable dose for two weeks prior to Study Day 0, and\n             will be continued at the same doses throughout the study.\n\n          7. Use of corticosteroids in excess of 10 mg prednisone or equivalent/day.\n\n          8. Known concurrent malignancy except basal or squamous cell skin carcinoma, or cervical\n             carcinoma in situ.\n\n          9. Concurrent participation in another clinical trial involving experimental treatment\n             within 30 days of Study Day 0.\n\n         10. Current and uncontrolled infection, cardiovascular, renal, pulmonary, hepatic or GI\n             conditions that will interfere with the conduct of the trial or pose a morbid risk.\n\n         11. Investigator's opinion that a concurrent disease or condition impairs the subject's\n             ability to complete the trial: includes psychological, familial, sociological,\n             geographical or medical conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724931", 
            "org_study_id": "Syntrix-AMT-RA-202"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "3 mg LD-Aminopterin", 
                    "1 mg LD-aminopterin"
                ], 
                "intervention_name": "LD-aminopterin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aminopterin", 
                "Folic Acid Antagonists", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "antifolate", 
            "antiinflammatory", 
            "autoimmune disease", 
            "hematological treatment", 
            "rheumatic disease", 
            "folic acid antagonist", 
            "enzyme inhibitor"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Donets'k", 
                        "country": "Ukraine", 
                        "zip": "83045"
                    }, 
                    "name": "Centre of Immunobiologic Therapy, State Institution \"Institute of Emergency and Reconstructive Surgery"
                }, 
                "investigator": [
                    {
                        "last_name": "Andriy Gnylorybov, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Viktoria Ridzhok, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Yuliia Hushchyna, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine", 
                        "zip": "83059"
                    }, 
                    "name": "Department of Hospital Therapy #1, Regional Clinical Hospital for occupational diseases 104"
                }, 
                "investigator": [
                    {
                        "last_name": "Vadym Berenfus, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Kristina Tyumyenyeva, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Vitaliy Tolstoy, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Viktoriia Balatsko, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine", 
                        "zip": "61137"
                    }, 
                    "name": "Communal Establishment of Health Protection, Regional Hospital of Veterans of War, Rheumatology Department"
                }, 
                "investigator": [
                    {
                        "last_name": "Anatolii Oparin, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Oleksii Oparin, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Natalia Lavrova, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kharkiv", 
                        "country": "Ukraine", 
                        "zip": "61178"
                    }, 
                    "name": "Department of Rheumatology, Communal Establishment of Health Protection \"Kharkiv City Clinical Hospital #8\""
                }, 
                "investigator": [
                    {
                        "last_name": "Vira Tseluyko, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Olha Radchenko, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyiv", 
                        "country": "Ukraine", 
                        "zip": "03151"
                    }, 
                    "name": "National Scientific Center \"M.D. STRAZHESKO INSTITUTE OF CARDIOLOGY, MAS OF UKRAINE\""
                }, 
                "investigator": [
                    {
                        "last_name": "Volodymyr Kovalenko, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Galyna Protsenko, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyiv", 
                        "country": "Ukraine", 
                        "zip": "04107"
                    }, 
                    "name": "Department of Rheumatology and Allergology, Kyiv Regional Clinical Hospital \u21161"
                }, 
                "investigator": [
                    {
                        "last_name": "Grygorii Lysenko, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ludmila Khimion, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Svetlana Danyliuk, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lviv", 
                        "country": "Ukraine", 
                        "zip": "79010"
                    }, 
                    "name": "Lviv Regional Clinical Hospital, Department of Rheumatology"
                }, 
                "investigator": [
                    {
                        "last_name": "Orest Abrahamovych, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ulyana Abrahamovych, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Iaryna Liaschuk, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Omelian Synenkii, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odesa", 
                        "country": "Ukraine", 
                        "zip": "65025"
                    }, 
                    "name": "Department of Cardio-Rheumatology, Communal Institution \"Odesa Regional Clinical Hospital\""
                }, 
                "investigator": [
                    {
                        "last_name": "Olena Levchenko, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Andriy Yurkiv, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maryna Kuznetsova, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Bogdana Scherbakova, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Simferopol", 
                        "country": "Ukraine", 
                        "zip": "95017"
                    }, 
                    "name": "Crimean State Medical University n.a. S.I. Georgievsky based on Rheumatology Department of Crimean Republic Institution \"Clinical Territorial Medical Association \"University Clinic\""
                }, 
                "investigator": [
                    {
                        "last_name": "Galyna Koshukova, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Andriy Petrov, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uzhorod", 
                        "country": "Ukraine", 
                        "zip": "88009"
                    }, 
                    "name": "Railway Clinical Hospital of Uzhorod Station of Lviv Railroad Administration, Therapeutic Department"
                }, 
                "investigator": [
                    {
                        "last_name": "Ivan Chopey, MD, PhD, Dr Sc D", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yaroslav Mykhalko, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Samvel Turianytsia, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vinnytsa", 
                        "country": "Ukraine", 
                        "zip": "21018"
                    }, 
                    "name": "Department of Rheumatology, Vinnytsya Regional Clinical Hospital n.a. M.I"
                }, 
                "investigator": [
                    {
                        "last_name": "Mykola Stanislavchuk, M.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Galyna Movchan, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhzhya", 
                        "country": "Ukraine", 
                        "zip": "69065"
                    }, 
                    "name": "Zaporizhzhya City Multiple Discipline Clinical Hospital #9, Department of Therapy"
                }, 
                "investigator": [
                    {
                        "last_name": "Volodymyr Koshlia, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ivan Isaichykov, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhzhya", 
                        "country": "Ukraine"
                    }, 
                    "name": "Department of Therapy, City Clinical Hospital \u2116 6"
                }, 
                "investigator": [
                    {
                        "last_name": "Oleg Kraydashenko, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Halyna Svetlytska, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Diana Buidenko, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhzhya", 
                        "country": "Ukraine", 
                        "zip": "69600"
                    }, 
                    "name": "Department of Rheumatology, Zaporizhzhia Regional Clinical Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Dmyto Rekalov, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ganna Prytkova, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Viktoria Krupko, M.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zaporizhzhya", 
                        "country": "Ukraine"
                    }, 
                    "name": "Department of Therapy, City Hospital \u2116 7"
                }, 
                "investigator": [
                    {
                        "last_name": "Vadym Vizir, M.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Oleksandr Goncharov, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anton Sadomov, M.D., Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Ukraine"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis", 
        "other_outcome": {
            "description": "Adverse events, including laboratory measurements of serum chemistry and hematology, and the occurrence of dose-limiting toxicity.  Safety endpoints will be evaluated throughout the study and for an additional 42 days after a subject goes off study.", 
            "measure": "Adverse Event", 
            "safety_issue": "Yes", 
            "time_frame": "Study Day 126"
        }, 
        "overall_contact": {
            "email": "Tetyana.Byelyayeva@kcrcro.com", 
            "last_name": "Tetyana Byelyayeva, M.D., Ph.D.", 
            "phone": "(+380 44) 499 56 00"
        }, 
        "overall_contact_backup": {
            "email": "Viktor.Dzyuba@kcrcro.com", 
            "last_name": "Viktor Dzyuba", 
            "phone": "(+380 44) 499 56 00"
        }, 
        "overall_official": {
            "affiliation": "Syntrix Biosystems, Inc.", 
            "last_name": "Stuart Kahn, MD, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ukraine: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint, determined at study day 84 or last observation carried forward (LOCF), is the percent of subjects who obtain ACR20 in the 3 mg/week LD-AMT dose compared to placebo.", 
            "measure": "ACR20", 
            "safety_issue": "No", 
            "time_frame": "Study Day 84"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724931"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "22653877", 
            "citation": "Menter A, Thrash B, Cherian C, Matherly LH, Wang L, Gangjee A, Morgan JR, Maeda DY, Schuler AD, Kahn SJ, Zebala JA. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J Pharmacol Exp Ther. 2012 Sep;342(3):696-708. doi: 10.1124/jpet.112.195479. Epub 2012 May 31."
        }, 
        "secondary_outcome": {
            "description": "A secondary efficacy endpoint, determined at study day 84 or LOCF, is the percent of subjects who obtain ACR20 in the 1 mg LD-AMT/week dose.", 
            "measure": "ACR20", 
            "safety_issue": "No", 
            "time_frame": "Study Day 84"
        }, 
        "source": "Syntrix Biosystems, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Syntrix Biosystems, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}